secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001606498-25-000106
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31
--------------------------------------------------------------------------------

- Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.
- Adjusted EPS $0.17 vs $0.34; adjusted EBITDA $17.0M vs $26.8M YoY.
- Recorded $77M goodwill impairment in PM&R segment due to market cap pressure.
- Divested HA product line (TriVisc, GenVisc 850) to Channel-Markers Medical on July 31, 2025.
- Appointed Scott Galovan as CFO effective Aug 1, 2025; CEO Pacitti appointed to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000106/0001606498-25-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000106/avns-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001606498-25-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer